DX-8951f in Treating Women Who Have Advanced or Recurrent Cancer of the Cervix

Completed · Phase 2

Conditions studied: Cervical Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating women who have advanced or recurrent cancer of the cervix.

Key facts

Study ID

NCT00004866

Run by

Daiichi Sankyo

Starts

2000-01-01

Expected to finish

2003-09-01

Last updated by the study team

2012-05-16

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• St. Luke's-Roosevelt Hospital — New York, New York, United States
• Albert Einstein Clinical Cancer Center — The Bronx, New York, United States
• Ruppert Health Center — Toledo, Ohio, United States
• Brookview Research, Inc. — Nashville, Tennessee, United States
• Texas Oncology PA (TOPA) at Baylor-Sammons — Dallas, Texas, United States
• University of Texas - MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.